Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 487

1.

Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.

Hirata S, Saito K, Kubo S, Fukuyo S, Mizuno Y, Iwata S, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.

Arthritis Res Ther. 2013 Sep 25;15(5):R135. doi: 10.1186/ar4315.

2.

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.

Tanaka Y, Hirata S, Kubo S, Fukuyo S, Hanami K, Sawamukai N, Nakano K, Nakayamada S, Yamaoka K, Sawamura F, Saito K.

Ann Rheum Dis. 2015 Feb;74(2):389-95. doi: 10.1136/annrheumdis-2013-204016. Epub 2013 Nov 28. Erratum in: Ann Rheum Dis. 2016 Jul;75(7):e46.

3.

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.

Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, Egerer K, Buttgereit F, Burmester GR.

Ann Rheum Dis. 2013 Jun;72(6):844-50. doi: 10.1136/annrheumdis-2012-201612. Epub 2012 Jun 27.

PMID:
22739990
4.

Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.

Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Sáez I, Unnebrink K, Kary S, Kupper H.

Arthritis Rheum. 2008 Jan 15;59(1):32-41. doi: 10.1002/art.23247.

5.

Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy.

Furst DE, Kavanaugh A, Florentinus S, Kupper H, Karunaratne M, Birbara CA.

Rheumatology (Oxford). 2015 Dec;54(12):2188-97. doi: 10.1093/rheumatology/kev249. Epub 2015 Jul 21.

PMID:
26199453
8.

How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?

Fleischmann R, van der Heijde D, Koenig AS, Pedersen R, Szumski A, Marshall L, Bananis E.

Ann Rheum Dis. 2015 Jun;74(6):1132-7. doi: 10.1136/annrheumdis-2013-204920. Epub 2014 Aug 20.

PMID:
25143522
9.

The efficacy of abatacept in Japanese patients with rheumatoid arthritis: 104 weeks radiographic and clinical results in clinical practice.

Mochizuki T, Yano K, Ikari K, Hiroshima R, Takaoka H, Kawakami K, Koenuma N, Shirahata T, Momohara S.

Mod Rheumatol. 2016 Jul;26(4):499-506. doi: 10.3109/14397595.2015.1109578. Epub 2015 Dec 23.

PMID:
26473281
10.
11.

Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.

Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, Singh G, Yamanaka H.

Ann Rheum Dis. 2008 Aug;67(8):1153-8. Epub 2007 Oct 30.

PMID:
17971459
12.

Twenty-four-week clinical results of adalimumab therapy in Japanese patients with rheumatoid arthritis: retrospective analysis for the best use of adalimumab in daily practice.

Kaneko A, Hirano Y, Fujibayashi T, Hattori Y, Terabe K, Kojima T, Ishiguro N.

Mod Rheumatol. 2013 May;23(3):466-77. doi: 10.1007/s10165-012-0705-y. Epub 2012 Aug 16.

PMID:
22895833
13.

Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.

Keystone EC, Haraoui B, Guérette B, Mozaffarian N, Liu S, Kavanaugh A.

J Rheumatol. 2014 Feb;41(2):235-43. doi: 10.3899/jrheum.121468. Epub 2013 Dec 1.

14.

Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.

Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Yamanaka H, Miyasaka N.

Rheumatology (Oxford). 2015 Apr;54(4):683-91. doi: 10.1093/rheumatology/keu338. Epub 2014 Sep 24.

15.

The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.

Salaffi F, Ciapetti A, Gasparini S, Carotti M, Bombardieri S; New Indices study group.

Clin Exp Rheumatol. 2012 Nov-Dec;30(6):912-21. Epub 2012 Dec 17.

PMID:
22935335
16.

Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability.

Pascual-Ramos V, Contreras-Yáñez I, Villa AR, Cabiedes J, Rull-Gabayet M.

Arthritis Res Ther. 2009;11(1):R26. doi: 10.1186/ar2620. Epub 2009 Feb 19.

17.

Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.

Wechalekar MD, Lester S, Proudman SM, Cleland LG, Whittle SL, Rischmueller M, Hill CL.

Arthritis Rheum. 2012 May;64(5):1316-22. doi: 10.1002/art.33506.

18.

The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab.

Hirabayashi Y, Ishii T; Michinoku Tocilizumab Study Group.

Clin Rheumatol. 2013 Jan;32(1):123-7. doi: 10.1007/s10067-012-2103-4. Epub 2012 Oct 23.

19.

Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.

Combe B, Logeart I, Belkacemi MC, Dadoun S, Schaeverbeke T, Daurès JP, Dougados M.

Ann Rheum Dis. 2015 Apr;74(4):724-9. doi: 10.1136/annrheumdis-2013-204178. Epub 2014 Jan 7.

PMID:
24399234

Supplemental Content

Support Center